Ensol Biosciences / 엔솔바이오사이언스
The website separately describes H1K, an oral anti-obesity candidate, and ESAIDD cyclic peptide discovery. This review could not confirm that H1K is cyclic or has human results.
South KoreaFull profile →
Find your next research lead.
All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
471 company identities · 13 technology & service fields
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
79 matching companies
AbbVie · Nimble Therapeutics
Co-commercializes approved LINZESS and holds regional rights, alongside oral peptide discovery through Nimble. ABBV-859 is in Phase 1; its exact structure and mapping to Nimble assets remain unconfirmed.
United StatesFull profile →
Gilead Sciences
On 2026-10-22, the company announced a proposed acquisition of PepStar's HCXT-2001 oral macrocyclic peptide program. Its Q3 announcement confirms Phase 1; closing conditions remain outstanding.
United StatesFull profile →
PepStar Therapeutics Limited
Counterparty for the HCXT-2001 transaction. Its role is recorded separately from Gilead's; the shared candidate is not counted as two independent drugs. The relationship between the Chinese sponsor and English legal entity requires confirmation.
China（香港）Full profile →
Pepticom
Uses AI to design oral IL-17A/F inhibitors. The company describes fully synthetic, compact cyclic peptidomimetics containing nonnatural amino acids.
Cyprumed
A September 2026 company announcement states that an unnamed MSD candidate using its oral technology entered Phase 1. The candidate structure is not disclosed, so it cannot be classified as a cyclic peptide.
AustriaFull profile →
Intract Pharma
Soteria provides protective excipients, Phloral provides targeted release, and UTAC provides active transport of macromolecules. Cyclic peptide applications require separate validation.
United KingdomFull profile →
Vivtex
The Novo collaboration uses gastrointestinal tissue screening and formulation platforms to develop oral biologics. Specific drugs and cyclic peptide structures have not been disclosed.
United StatesFull profile →
Enteris BioPharma
Peptelligence previously conducted feasibility studies with Ferring to convert injectable peptides into oral formulations. It is retained as a historical delivery approach; current operations and ownership require verification.
United StatesFull profile →
Entera Bio
EB613 is oral PTH(1-34), with disclosed clinical results and new-formulation bridging data and a planned Phase 3 program. Human evidence for this linear peptide is used only as a platform reference.
Rani Therapeutics
RaniPill is a swallowable robotic capsule. RT-101 octreotide is a historical human development program whose current activity is unconfirmed, recorded separately from conventional intestinal permeation enhancement.
United StatesFull profile →
Novartis
NEORAL cyclosporine is a classic benchmark for oral cyclic peptides and microemulsion preconcentrates; it should not be assumed bioequivalent to Sandimmune.
SwitzerlandFull profile →
Ironwood Pharmaceuticals
LINZESS (linaclotide) is an oral peptide with multiple disulfide bonds and a GC-C agonist acting locally in the gastrointestinal tract. Systemic bioavailability is not the primary success criterion.
United StatesFull profile →
Bausch Health / Salix
TRULANCE (plecanatide) is an oral disulfide-constrained peptide and GC-C agonist acting locally in the gastrointestinal tract. Regional status is based on the Canadian product monograph reviewed.
Canada / United StatesFull profile →
Ferring Pharmaceuticals
Swallowed DDAVP desmopressin tablets are a classic oral disulfide peptide reference. Swallowed, orally disintegrating, and sublingual products should be recorded separately.
SwitzerlandFull profile →
Dayra Therapeutics
Collaborates with Biogen to discover and optimize oral macrocyclic peptides for immune diseases. Named targets, candidates, and human results have not been disclosed.
CanadaFull profile →
Biogen
Industry partner for Dayra's oral macrocyclic peptide collaboration, responsible for subsequent development and potential commercialization. Its role is recorded separately from Dayra's using a shared program identifier.
United StatesFull profile →
argenx
Conducts multi-target oral macrocyclic peptide research with Unnatural Products. Evidence supporting marketed antibody products does not raise the evidence grade of the macrocycle program.
Netherlands / Belgium / United StatesFull profile →
AstraZeneca
Entered chronic-disease macrocyclic peptide research through the Syneron Bio collaboration. No named clinical oral candidate from that collaboration has been disclosed.
United Kingdom / SwedenFull profile →
Novo Nordisk
Works with Orbis on oral macrocycle discovery and with Vivtex on delivery. Success with oral semaglutide does not automatically validate the collaborative macrocycle program.
Sungening Biotech
SG6001 is an oral PCSK9 cyclic peptide. Official materials confirm a preclinical program and an out-licensing strategy; clinical status of other antifungal candidates is not applied to this program.
ChinaFull profile →
Palatin Technologies
PL8177 is a colon-delivered cyclic heptapeptide MC1R agonist. The company reported Phase 2 UC proof of concept and explicitly welcomes partnerships / licensing.
United StatesFull profile →
Debiopharm
Alisporivir (Debio 025) is a cyclosporine-derived cyclophilin inhibitor with historical clinical development. A 2021 trial does not establish current active status.
SwitzerlandFull profile →
XtalPi
PepiX™ connects AI, automated synthesis, and experimental screening. The website identifies oral cyclic peptides as a priority; food-peptide GRAS status is not pharmaceutical evidence.
ChinaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.